Responses
Drug Information and Pharmacotherapy
DI-033 Safety profile study of planned randomised conversion from tacrolimus to sirolimus-based immunosuppressive regimen in de novo kidney transplant recipients
Compose a Response to This Article
Other responses
No responses have been published for this article.